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EDITORIAL
New Initiatives in Phlebology
Phlebology, the study of the veins, has for too long
been regarded as the poor relation of peripheral arter-
ial disease. However, over the last one to two decades,
basic science and clinical research has brought huge
advances in our understanding of the pathophysiol-
ogy of venous disease which in turn has driven the
implementation of evidence-based clinically and cost-
effective treatments. The widespread availability of
duplex ultrasound, the existence for the first time of
an internationally accepted classification (CEAP), our
increasing understanding of the haemostatic and fibri-
nolytic pathways, the acceptance of the randomised
controlled trial (RCT) as the only means of answering
basic questions relating to the medical and surgical
management of chronic venous insufficiency, and the
growing use of health-related quality of life as a valid
outcome measure are worthy of particular mention.
The increasing profile and stature of phlebology as a
respected sub-specialty in its own right is witnessed
by the formation and success of societies such as the
Venous Forum of the Royal Society of Medicine in
the U.K., and the American Venous Forum and the
North American Society of Phlebology, now known as
the American College of Phlebology, in the U.S.A.
There are many other examples. These societies con-
tinue to stimulate interest in the clinical practice of
phlebology as well as considerable basic science and
clinical research. They also offer a wealth of infor-
mation and support to consumers (patients) and
practitioners.
Until recently, many treatments for venous disease
such as surgery, sclerotherapy and bandaging had
changed little in decades, centuries, even millennia!
However, all these techniques are undergoing critical
evaluation and refinement. Specifically, RCT data
have helped us to optimise the prevention and
treatment of venous thrombo-embolism, maximise
the benefits of compression therapy, understand that
stripping of the long saphenous vein in the thigh is
essential to prevent varicose vein recurrence and that
superficial venous surgery in addition to compression
significantly improves the natural history chronic
venous ulceration when compared to compression
alone. Examples of exciting new minimally invasive
therapies include radio-frequency ablation of the
saphenous vein, endovenous laser treatment and
ultrasound guided foam sclerotherapy. These
advances have been made possible through the devel-
opment of closer and more trusting relationships
between phlebologists, scientists, industry and the
regulatory authorities. While optimisation of these
new methods will require considerable further
research, it is likely that in the future the treatment
of most venous disease will be unrecognisable. In
short, there has never been a more exciting and
rewarding time to be a phlebologist.
Many readers will know that we have both previ-
ously edited the journal `` Phlebology''. Several other
groups are currently publishing journals devoted to
diseases of the veins. However, it is sad to say that
none of these journals has ever been listed in Index
Medicus, or reached sufficient standing in their own
right to attract world-class venous research. The enor-
mously successful relationship between the American
Venous Forum and the Journal of Vascular Surgery
has no European equivalent. The European Journal
of Vascular Surgery, renamed the European Journal
of Vascular and Endovascular Surgery to reflect its
broader appeal and readership, continues to thrive.
While the EJVES has always published the occasional
venous paper, the Editorial Board saw an unmet need
in the field of phlebology and we were delighted to
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accept their kind invitation to launch and edit a new
section devoted to venous disease.
We hope and believe that this new section will
benefit clinicians, scientists and, of course, ultimately
patients through the publication and widespread
dissemination of high-quality venous papers in a
well-respected, indexed journal that exists in both
manuscript and internet forms. This issue includes
the first Phlebology section. We invite comments and
criticisms and, of course, manuscripts!
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